Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: Unfolding the relationship between pharmacokinetics and pharmacodynamics

Molecular Cancer Therapeutics

Volumn 2, Issue 2, 2003, Pages 131-138

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; PROTEIN SERINE THREONINE KINASE; RIFABUTIN;

DRUG ANTAGONISM; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEOPLASM; NOTE;

BENZOQUINONES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RIFABUTIN;

EID: 0043269344     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Note

References (44)

1. Workman, P. Challenges of PK/PD measurements in modern drug development. Eur. J. Cancer, 38: 2189-2193, 2002. (Pubitemid 35223253)
2. Peck, C. C., Barr, W. H. Benet, L. Z., Collins, J., Desjardins, R. E., Furst, D. E., Harter, J. G., Levy, G., Ludden, T., and Rodman, J. H. Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin. Pharmacol. Ther., 51: 465-473, 1992.
3. Chiosis, G., Huezo, H., Rosen, N., Mimnaugh, E., Whitesell, L., and Neckers, L. 17AAG: low-target binding affinity and potent cell activity-finding an explanation. Mol. Cancer Ther., 2: 123-129, 2003.
4. Workman, P., and Graham, M. A. (eds.), Pharmacokinetics and Cancer Chemotherapy. Cancer Surveys, Vol. 17. Cold Spring Harbor, New York: Cold Spring Harbor Press, 1993.
5. Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. In: Radiolabelled Compounds for Drug Discovery and Development (Ed Cook, GRJ), Current Pharmaceutical Design, in press, 2003.
6. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med., 8 (Suppl.): S55-S61, 2002. (Pubitemid 34297080)
7. Maloney, A., and Workman, P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther, 2: 3-24, 2002. (Pubitemid 34462457)
8. Weinstein, I. B. Addiction to oncogenes. Science (Wash. DC), 297: 63-64, 2002.
9. Evan, G. I., and Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer research. Nature (Lond.), 411: 342-348, 2001. (Pubitemid 32467043)
10. Prodromou, C., and Pearl, L. H. Structure and in vivo function of Hsp90. Curr. Opin. Struct. Biol., 10: 46-51, 2000. (Pubitemid 30099326)
11. Supko, J. G., Hickman, R. L., Grever, M. R., and Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent. Cancer Chemother. Pharmacol., 36: 305-310, 1995.
12. Schulte, T. W., and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamcyin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998. (Pubitemid 28393843)
13. Munster, P. N., Srethapakdi, M., Moasser, M. M., and Rosen, N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res., 61: 2945-2952, 2001. (Pubitemid 32691939)
14. Hostein, I., Robertson, D., Di Stefano, F., Workman, P., and Clarke, P. A. Inhibition of signal transduction by 17-allylamino-17-demethoxy-geldanamycin results in cytostasis and apoptosis. Cancer Res., 61: 4003-4009, 2001. (Pubitemid 32720963)
15. Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., and Workman, P. DT-diaphorase expression and tumor cell sensitivity to 17- allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. (Bethesda), 91: 1940-1949, 1999.
16. Solit, D. B., Zheng, F. F., Drobnjal, M., Munster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W., Cardon-Cordo, C., Agus, D. B., Scher, H. I., and Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 8: 986-993, 2002. (Pubitemid 34517631)
17. Basso, A. D., Solit, D. B., Munster, P. N., and Rosen, N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 21: 1159-1166, 2002. (Pubitemid 34185232)
18. Smith, V., Sausville, E. A., Camalier, R. F., Fiebig, H. H., and Burger, A. M. 17-DMAG (NSC 707545), a water-soluble geldanamycin analog, has superior in vitro and in vivo antitumour activity compared to the hsp90 inhibitor 17-AAG. Eur. J. Cancer, 38 (Suppl. 7): S60, 2002.
19. Agnew, E. B., Wilson, R. H., Morrison, G., Neckers, L. M., Takimoto, C., H., and Grem, J. L. Clinical pharmacokinetics of 17-(allylamino)-17- demethoxygeldanamycin and the active metabolite 17-(allylamino)-17- demethoxygeldanamycin given as a one-hour infusion daily for 5 days. Proc. Am. Assoc. Cancer Res., 43: 1349, 2002.
20. Wilson, R. H., Takimoto, C. H., Agnew, E. B., Morrison, G., Grollman, F., Thomas, R. R., Saif, M. W., Allegra, C., Grochow, L., Szabo, E., Hamilton, J. M., Monahan, B. P., Neckers, L., and Grem, J. L. Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumours. Proc. Am. Soc. Clin. Oncol., 20: 82a, 2001.
21. Munster, P. N., Tong, W. Schwartz, L., Larson, S., Kenneson, K., De La Cruz, A., Rosen, N., and Scher, H. Phase I trial of 17-(allylamino)-17- demethoxygeldanamycin (17AAG) in patients (Pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol., 20: 83a, 2001.
22. Banerji, U., O'Donnell, A., Scurr, M., Benson, C., Hanwell, J., Clark, S., Raynaud, F., Turner, A., Walton, M., Workman, P., and Judson, I. Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-(allylamino)-17- demethoxygeldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc. Am. Soc. Clin. Oncol., 20: 82a, 2001.
23. Banerji, U., O'Donnell, A., Scurr, M., Benson, C., Brock, C., Hanwell, J., Stapleton, S., Raynaud, F., Simmons, L., Turner, A., Walton, M., Workman, P., Judson, I. A. pharmacokinetically (PK)-pharmacodynamically (PD) driven Phase I trial of the Hsp90 molecular chaperone inhibitor 17-(allylamino)-17- demethoxygeldanamycin (17AAG). Proc. Am. Assoc. Cancer. Res., 43: 1352, 2002.
24. Erlichman, C., Toft, D., Reid, J., Sloan, J., Atherton, P., Adjel, A., Ames, M., and Croghan, G. A Phase 1 trial of 17-allyl-amino-geldanamycin in patients with advanced cancer. Proc. Am. Assoc. Cancer Res., 42: 4474, 2001.
25. Panaretou, B., Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J., 17: 4829-4836, 1998. (Pubitemid 28377183)
26. Roe, S. M., Prodromou, C., O'Brien. R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin. J. Med. Chem., 42: 260-266, 1999. (Pubitemid 29069861)
27. Chiosis, G., Rosen, N., and Sepp-Lorenzino, L. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg. Med. Chem. Lett., 11: 909-913, 2001. (Pubitemid 32226213)
28. Egorin, M. J., Sentz, D. L., Zuhowski, E. G., Dobson, J. M., Schulte, T. W., Neckers, L. M., and Eiseman, J. L. PC3 human prostate xenograft retention of, and oncoprotein modulation by, 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in vivo. Proc. Am. Assoc. Cancer Res., 40: 3409, 1999.
29. Egorin, M. J., Rosen, D. M., Wolff, J. H., Callery, P. S., Musser, S. M., and Eiseman, J. L. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res., 58: 2385-2396, 1998. (Pubitemid 28252699)
30. Smith, V., Hobbs, S., Court, W., Eccles, S., Workman, P., and Kelland, L. R. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res., 22: 1993- 2000, 2002.
31. Morimoto, R. I. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev., 12: 3788-3796, 1998. (Pubitemid 29024840)
32. Clarke, P. A., Hostein, I., Banerji, U., DiStefano, F., Maloney, A., Walton, M., and Workman, P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17- demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene, 19: 4125-4133, 2000.
33. Banerji, U., Walton, M., Raynaud, F., Kelland, L., Judson, I., and Workman, P. Validation of pharmacodynamic endpoints for the Hsp90 molecular chaperone inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG) in a human tumor xenograft model. Proc. Am. Assoc. Cancer Res., 42: 4473, 2001.
34. Panaretou, B., Giligardi, G., Meyer, P., Maloney, A., Sullivan, J. K., Singh, S., Millson, S. H., Clarke, P. A., Naaby-Hansen, S., Stein, R., Cramer, R., Mollapour, M., Workman, P., Piper, P. W., Pearl, L. H., and Prodromou, C. Activation of ATPase activity of Hsp90 by the stressregulated cochaperone Aha1. Mol. Cell, 10: 1307-1318, 2002. (Pubitemid 36050873)
35. Stepanova, L., Leng, X., Parker, S. B., and Harper, J. W. Mammalian p50cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes CDK4. Genes Dev., 10: 1491-1502, 1996. (Pubitemid 26260706)
36. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Cancer Rev., 2: 1-8, 2002.
37. Chung, Y. L., Troy, H., Banerji, U., Judson, I., Leach, M., Stubbs, M., Ronen, S., Workman, P., and Griffiths, J. The pharmacodynamic effects of 17-AAG on HT29 xenografts in mice monitored by magnetic resonance spectroscopy. Proc. Am. Assoc. Cancer Res. 43: 73, 2002.
38. Lui, D., Hutchinson, O. C., Osman, S., Price, P., Workman, P., and Aboagye, E. O. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br. J. Cancer, 87: 783-789, 2002. (Pubitemid 35178757)
39. Munster, P. N., Basso, A., Solit, D., Norton, L., and Rosen, L. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001. (Pubitemid 32751619)
40. Chiosis, G., Timaul, M. N., Lucas, B., Munster, M. N., Zheng, F. F., Sepp-Lorenzino, L., and Rosen, N. A. small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol., 8: 289-299, 2001. (Pubitemid 32296118)
41. Chiosis, G., Huezo, H., Lucas, B., and Rosen, N. Development of a purine-based novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem., 10: 3555-3564, 2002.
42. Marcu, M. G., Chadli, A., Bouhouche, I., Catelli, M., and Neckers, L. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem., 275: 37181-37186, 2000. (Pubitemid 32002137)
43. Rowlands, M. G., Newbatt, Y. M., Turlais, F., Prodromou, C., Pearl, L., Workman, P., and Aherne, W. High throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Clin. Cancer Res., 7 (Suppl.): s475, 2001.
44. Beroza, P., Meng, F., Bears, D. J., Egle, T. A., Futsner, B. W., Watts, G., Whitesell, L., Lin, P., Grossman, E., Dao-pick, T., Damodaran, K., Laborde, E., Schow, S., Keck, J. G., Martin, G. R., Gomez, R. F., and Wick, M. Efficient discovery of novel small molecule cancer drugs using Telik's target-related affinity profiling (TRAP™) technology. Proc. Am. Assoc. Cancer Res., 43: 37, 2002.